Not Yet RecruitingPhase 1/2

EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

United States30 participantsStarted 2026-09

Plain-language summary

This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Pathologically confirmed pancreatic adenocarcinoma.
. Clinically staged locally advanced or borderline resectable pancreatic adenocarcinoma.
. Completed neoadjuvant chemotherapy
. Neoadjuvant radiation is allowed
. Planned surgical exploration
. Treatment with ASP-1929 will be at least 4 - 10 weeks after last chemotherapy and radiation.
. Patients with a history of biliary obstruction must have adequate biliary drainage.
. Patients meeting the following laboratory criteria for Adequate Organ and Bone Marrow Function:

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Incidence of treatment related toxicities grade ≥3

Timeframe: From start of treatment to 28 days post surgery

Number of Participants Reaching 6 Months Progression Free Survival

Timeframe: From start of treatment to 6 months post surgery.

Trial details

NCT IDNCT07698613

SponsorBrown University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-03

Contact for this trial

Roxanne Wood, MPH

401-863-3000 roxanne_wood@brown.edu

View on ClinicalTrials.gov More Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Pathologically confirmed pancreatic adenocarcinoma.
. Clinically staged locally advanced or borderline resectable pancreatic adenocarcinoma.
. Completed neoadjuvant chemotherapy
. Neoadjuvant radiation is allowed
. Planned surgical exploration
. Treatment with ASP-1929 will be at least 4 - 10 weeks after last chemotherapy and radiation.
. Patients with a history of biliary obstruction must have adequate biliary drainage.
. Patients meeting the following laboratory criteria for Adequate Organ and Bone Marrow Function:

EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Contact for this trial

EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

Plain-language summary

Who can participate

Inclusion criteria

Questions worth asking your doctor

Questions for the trial coordinator

What they're measuring

Trial details

Contact for this trial

Exclusion criteria